Pulse Check: What’s New in Cardiology

Share This Event

*Registration payment includes Credit Cards and Interfund Transfers ONLY.

Target Audience

Pharmacists

Description

This knowledge-based CPE activity will provide attendees with an evidence-based update on emerging therapies, landmark clinical trials, and evolving guideline recommendations in cardiovascular care. This session will review contemporary management strategies across key cardiology topics including dyslipidemia, cardiometabolic conditions, and hypertension, with emphasis on translating new evidence into clinical pharmacy practice. Practical considerations for medication selection, monitoring, and patient counseling will also be discussed.

Live Webinar Information
This webinar will be broadcast with Zoom. Instructions to join the webinar will be emailed prior to the event. Please go to our live webinar requirements page for more information and to test the computer/device and network prior to the event.


Continuing Education Credit For Pharmacists:
The University Of North Carolina Eshelman School Of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. The program ACPE #0046-9999-26-148-L01-P(Pharmacist) provides 2.0 contact hours of continuing pharmacy education credit. To receive CE credit, you must complete the CE attendance form and the evaluation of the program. Statement of credit can be viewed and printed in CPE Monitor. Statements of CE Credit will be processed in approximately 2 to 3 weeks. **No partial credit will be available**

Registering for and attending a South Piedmont AHEC program authorizes South Piedmont AHEC to take audio, video, and/or still images to be used for promotional and educational purposes. If you have concerns, please speak with a South Piedmont AHEC team member.

Objectives

• Review recent guideline updates and landmark clinical trials impacting cardiovascular pharmacotherapy.
• Compare contemporary treatment strategies for common cardiovascular disease states, including dyslipidemia, cardiometabolic conditions, and hypertension.
• Identify emerging therapies and evolving evidence in cardiometabolic and cardiovascular risk reduction.
• Recall current evidence and guideline recommendations to optimize patient-centered cardiovascular care.

Sessions